Lp(a)

Lipoprotein(a), abbreviated Lp(a), is an LDL-like particle with an extra protein (apolipoprotein(a)) covalently bound to ApoB. It is almost entirely genetically determined, set by mid-childhood, and largely unmoved by diet, exercise, or statins. Elevated Lp(a) is one of the most under-recognized inherited cardiovascular risk factors. Every adult should measure it once, full stop.

Optimal range

Range varies by individual.

Test frequency

Once per lifetime for screening; repeat only if values fall in a borderline range or if a future Lp(a)-lowering therapy makes treatment-monitoring relevant.

When to measure

Measure once in adulthood, ideally before age 40. Lp(a) levels are set genetically and change minimally over time, so a single measurement is sufficient unless treatment-specific re-measurement becomes relevant. If the first value is borderline (40–60 mg/dL), repeat once with an isoform-insensitive assay to confirm. Anyone with a family history of premature cardiovascular disease, unexplained early stroke, or aortic stenosis should measure at the first opportunity, regardless of age.

How to measure

Serum measurement, either as mass (mg/dL) or particle concentration (nmol/L); the nmol/L assays are now preferred because they are less affected by Lp(a) isoform size variation. Cost is typically $30–$80 retail; rarely included in default lipid panels and almost always requires an explicit physician request. No fasting required.

Why this biomarker matters

Lp(a) is independently atherogenic, pro-thrombotic, and pro-inflammatory. Above the population threshold of roughly 50 mg/dL (or 125 nmol/L),which characterizes about 20 percent of adults, it confers two- to four-fold increased risk of coronary artery disease, ischemic stroke, and calcific aortic valve stenosis, on top of whatever ApoB or LDL-C risk a person also carries. The combination of high Lp(a) with high ApoB is particularly dangerous, and high Lp(a) in someone with otherwise pristine lipids should still trigger aggressive risk-factor management. Because Lp(a) is essentially unmodifiable by lifestyle, the treatment paradigm is to drive ApoB very low to offset the risk. PCSK9 inhibitors reduce Lp(a) modestly (15–30 percent); niacin reduces it inconsistently. The pipeline therapies, pelacarsen (an antisense oligonucleotide) and olpasiran (an siRNA),both reduce Lp(a) by 80 to 90 percent in phase 2 trials. Outcome trials read out over the next several years and are expected to define a new standard of care for elevated-Lp(a) patients.

The prime report

Weekly performance intelligence.

New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.